<div>Gene therapy has the potential to revolutionise medicine, offering the possibility of real treatments for conditions that were once considered untreatable. For children born with genetic disorders, this technology represents more than just hope—it offers the potential to change lives, giving them opportunities for greater independence, mobility, and communication. Scientific breakthroughs have brought gene therapy to the brink of transforming paediatric medicine, but funding remains a critical barrier. Right now, £300,000 stands between a life-changing gene therapy and the children who need it. Without this funding, a treatment that could make a profound difference will remain out of reach, delaying progress not just for one condition, but for the future of gene therapy as a whole.
</div>
<div><br />
</div>
<div>Our daughter was born with CTNNB1 syndrome. When she was small, particularly in those early months, we believed she was just taking her time, that every baby develops at their own pace. But as the weeks turned into months, we began to notice the small things—milestones that should have come but did not. Her movements were slower, her muscles softer, and the words we longed to hear never arrived. At first, we reassured ourselves. Maybe she was just on her own schedule. Maybe everything would even out. But deep down, an uneasy feeling grew. We watched other children pull themselves up, take their first steps, say their first words, while our daughter remained in a world that seemed to move differently for her. The gradual realisation that something was wrong was not a single moment, but a slow, creeping weight—hope and worry twisting together until the day we heard the words that changed everything: a rare genetic condition.
</div>
<div><br />
</div>
<div>No parent ever imagines this path. No one prepares for the countless therapies, the medical appointments, the sleepless nights spent searching for answers. And yet, here we are—standing at the edge of a breakthrough that could rewrite her future. A gene therapy exists that could treat the very cause of her condition, offering possibilities we never thought we would have. But like so many medical breakthroughs, it is just out of reach—not because it does not work, but because the funding to take it to clinical trial has not yet been secured
</div>
<div><br />
</div>
<div>Children with CTNNB1 Syndrome are bright, determined, and full of personality. They find ways to connect, communicate, and experience joy in their own unique ways. But every day, they face challenges that most people never have to think about. A simple movement—lifting a cup, taking a step—can require immense effort. Speech may not come at all, leaving children unable to express their needs, thoughts, or feelings in the ways they want to. Many cannot walk, struggle with coordination, or experience seizures and serious medical complications. Therapies help, but they can only do so much. The underlying cause—a single genetic mutation—remains unchanged.
</div>
<div><br />
</div>
<div>But for the first time, there is a treatment that could change this.
</div>
<div><br />
</div>
<div><strong>The First Gene Therapy for CTNNB1 Syndrome Is Ready</strong>
</div>
<div><br />
</div>
<div>A gene therapy has already been developed and manufactured. It is one of the highest-quality products ever produced by its manufacturing partner, and it has been recognised by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) as a promising therapy.
</div>
<div><br />
</div>
<div>This could be the breakthrough that children with CTNNB1 Syndrome desperately need. A treatment that does more than manage symptoms—one that could target the root cause.
</div>
<div><br />
</div>
<div>The only barrier left? Funding.
</div>
<div><br />
</div>
<div><strong>£300,000 must be raised to move the treatment into clinical trial</strong>s. Until that happens, the therapy cannot be used, and families remain in a painful waiting game—knowing that something exists but not being able to access it.
</div>
<div><br />
</div>
<div><strong>A Step Towards Transforming Medicine for Other Genetic Conditions</strong>
</div>
<div><br />
</div>
<div>CTNNB1 Syndrome is just one of thousands of genetic conditions caused by a single-gene mutation. Many, like<strong> Angelman Syndrome</strong> and <strong>Rett Syndrome</strong>, share similar challenges: severe movement and communication difficulties, high support needs, and no cure.
</div>
<div><br />
</div>
<div><strong>Gene therapy offers a real pathway to change</strong>. The success of this trial could set the stage for other conditions to follow, opening doors for more research, faster approvals, and <strong>a future where genetic disorders can be treated—not just managed.</strong>
</div>
<div><br />
</div>
<div>This is bigger than one condition. <strong>It is about proving that gene therapy can and should be an option for children who would otherwise be left with no medical solutions</strong>.
</div>
<div><br />
</div>
<div>Time Is Running Out. The Trial Cannot Move Forward Without This Funding.
</div>
<div><br />
</div>
<div>A treatment is ready. The research has been done. The approval process is within reach. But none of that matters without funding.
</div>
<div><br />
</div>
<div>Every delay means more time lost—time when children could be receiving life-changing treatment.
</div>
<div><br />
</div>
<div><strong>Donations, no matter the amount, bring this one step closer to reality.</strong>
</div>
<div><br />
</div>
<div>Share this, donate, and help make sure that this therapy does not sit on a shelf when it could be changing lives.
</div>
<div><br />
</div>
<div><strong>Because when a breakthrough like this is possible, it should not be out of reach.</strong>
</div>
<div><br />
</div>
<div>ALL DONATIONS WILL GO DIRECTLY TO THE CTNNB1 FOUNDATION
</div>
<div><br />
</div>
<div>CTNNB1 Foundation, The Gene Therapy Research Institute
</div>
<div>Address: Dalmatinova ulica 5, Ljubljana
</div>
<div>Registration Number: 4125878000
</div>
<div><br />
</div>
<div><a href="https://ctnnb1-foundation.org/wp-content/uploads/2025/03/CTNNB1-Foundation-Financial-Report-2025.pdf?fbclid=IwY2xjawJDaaFleHRuA2FlbQIxMAABHcA-JQvL0XaQVMNiB60PjIY6aobwbfX01JVSFO6rk35xpkLI5NnGZiFQbA_aem_1YYYOU_F8v_IJcGYHsQhjw" target="_blank" rel="noreferrer noopener"><a href="https://ctnnb1-foundation.org/wp-content/uploads/2025/03/CTNNB1-Foundation-Financial-Report-2025.pdf?fbclid=IwY2xjawJDaaFleHRuA2FlbQIxMAABHcA-JQvL0XaQVMNiB60PjIY6aobwbfX01JVSFO6rk35xpkLI5NnGZiFQbA_aem_1YYYOU_F8v_IJcGYHsQhjw" target="_blank" class="" rel="nofollow noopener noreferrer">https://ctnnb1-foundation.org/wp-content/uploads/2025/03/CTNNB1-Foundation-Financial-Report-2025.pdf?fbclid=IwY2xjawJDaaFleHRuA2FlbQIxMAABHcA-JQvL0XaQVMNiB60PjIY6aobwbfX01JVSFO6rk35xpkLI5NnGZiFQbA_aem_1YYYOU_F8v_IJcGYHsQhjw</a></a>
</div>

Deborah Monerawela

Anonymous

Maria Muzaffer

Peter Smith

Emma Welsby

catherine welsby

Andrew Darbyshire

Carla Deeks

Chris Galberg

Pamela Kirsch

Michael Kerfoot

Toby Martin

Lorna McKelvey

Emily Atkinson

The Future of Gene Therapy Starts Here – Fund the Final Step

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

The Future of Gene Therapy Starts Here – Fund the Final Step

Still £41,875 to go. Help us build momentum.